ATRC AtriCure, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1323885 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.8%
TTM net income YoY151.7%
TTM EPS YoY150.8%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—
Margins
Gross margin76.7%
Operating margin2.9%
Net margin2.5%
FCF margin9.0%
EBITDA margin4.9%
Returns
ROE2.9%
ROA2.2%
ROIC (approx.)3.9%
Asset turnover0.87x
Leverage & solvency
Liabilities / assets25.7%
Debt / equity0.11x
Current ratio4.33x
Interest coverage2.95x
Cash quality & payout
Operating cash flow / net income4.61x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $534.53M | $465.31M | $399.25M | $330.38M | $274.33M |
| Cost of revenue | $133.75M | $117.78M | $98.88M | $84.44M | $68.47M |
| Gross profit | $400.78M | $347.52M | $300.37M | $245.94M | $205.86M |
| R&D expense | $99.21M | $96.18M | $73.92M | $57.34M | $48.51M |
| SG&A expense | $311.02M | $291.36M | $253.14M | $231.27M | $204.65M |
| Operating income | -$9.45M | -$40.01M | -$26.68M | -$42.67M | $55.20M |
| Interest expense | $5.88M | $6.41M | $6.92M | $4.99M | $4.92M |
| Pretax income | -$10.16M | -$43.67M | -$29.85M | -$46.20M | $50.39M |
| Income tax | $1.28M | $1.02M | $591,000 | $268,000 | $188,000 |
| Net income | -$11.45M | -$44.70M | -$30.44M | -$46.47M | $50.20M |
| EBITDA | $2.64M | -$28.80M | -$17.22M | -$34.61M | $62.74M |
| EPS (basic) | -0.24 | -0.95 | -0.66 | -1.02 | 1.11 |
| EPS (diluted) | -0.24 | -0.95 | -0.66 | -1.02 | 1.09 |
| Weighted avg. shares (diluted) | 47.75M | 46.97M | 46.31M | 45.74M | 46.04M |
| Balance sheet | |||||
| Cash & equivalents | $167.43M | $122.72M | $84.31M | $58.10M | $43.65M |
| Short-term investments | — | $0 | $52.98M | $63.01M | $75.44M |
| Receivables | $66.65M | $60.34M | $52.50M | $42.69M | $33.02M |
| Inventory | $78.49M | $75.33M | $67.90M | $45.93M | $38.96M |
| Current assets | $322.52M | $267.83M | $266.25M | $215.21M | $196.08M |
| PP&E, net | $39.12M | $41.66M | $42.44M | $38.83M | $31.41M |
| Goodwill | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M |
| Intangibles | $48.03M | $56.47M | $63.99M | $39.34M | $42.99M |
| Total assets | $654.18M | $609.33M | $613.93M | $585.45M | $615.31M |
| Current liabilities | $81.52M | $73.42M | $74.57M | $58.39M | $56.45M |
| Short-term debt | — | $2.81M | $2.53M | $5.47M | — |
| Long-term debt | $61.87M | $61.87M | $60.59M | $56.83M | $59.74M |
| Total debt | $61.87M | $64.67M | $63.13M | $62.31M | $59.74M |
| Total liabilities | $162.24M | $148.36M | $147.76M | $128.69M | $131.56M |
| Shareholders' equity | $491.94M | $460.97M | $466.17M | $456.75M | $483.76M |
| Net debt | -$105.56M | -$58.05M | -$21.18M | $4.21M | $16.09M |
| Shares outstanding | 49.79M | 48.87M | 47.53M | 46.56M | 46.02M |
| Cash flow statement | |||||
| Operating cash flow | $57.33M | $12.20M | $4.48M | -$22.14M | -$13.78M |
| Capital expenditure | $9.05M | $11.46M | $12.00M | $16.88M | $9.75M |
| Free cash flow | $48.28M | $745,000 | -$7.51M | -$39.02M | -$23.53M |
| Investing cash flow | -$14.55M | $30.23M | $21.82M | $44.01M | $23.50M |
| Financing cash flow | $1.18M | -$3.60M | -$32,000 | -$7.06M | -$7.64M |
| Depreciation & amortization | $12.09M | $11.21M | $9.46M | $8.06M | $7.53M |
| Stock-based compensation | $44.69M | $40.41M | $35.73M | $28.77M | $28.08M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.